Abstract Library

#3512 Genetic, epigenetic and/or transcriptional profiling of 14q genes, MAX and MEG3 in pituitary neuroendocrine tumors

Introduction: Recent studies have identified a growing series of susceptibility genes for pituitary neuroendocrine tumors (PitNETs) and pheochromocytomas/paragangliomas (PPGL). Some of these genes (e.g., SDH genes) have be specifically associated with the development of these pathologies.

Conference:

Presenting Author: Ibáñez Costa A

Authors: Ibáñez-Costa A, Letón R, Rivero-Cortés E, Álvarez-Escolá C, Rodriguez Poyo-Guerrero P,

Keywords: pituitary tumor, epigenetics, MAX, genomics,

#3201 Safety and efficacy of peptide receptor radionuclide therapy in treating high-risk patients with extensive neuroendocrine tumors

Introduction: Neuroendocrine tumors (NETs) are a rare group of neoplasms. Peptide receptor radionuclide therapy (PRRT) is a well-recognized treatment modality for NETs that express somatostatin receptors (SSRs) on neuroendocrine cells’ surface. While many studies assessed the efficacy and safety in all NET patients, only a few focused on high-risk patients.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Alsadik S, Gnanasegaran G, Chen L, Toumpanakis C, Caplin M,

Keywords: neuroendocrine tumor, NET, peptide receptor radionuclide therapy PRRT, 177lu-DOTATATE, extensive liver metastases, extensive skeletal metastases, extensive tumor burden,

#3075 Telotristat Makes Significant Difference on Symptoms and Serotonin Levels in a Population with Widespread GI-NET and Severe Carcinoid Syndrome

Introduction: In spite of new treatments like PRRT or everolimus there is a clinical need for systemic therapies that complement SSAs (somatostatin analogs) and antidiarrheal agents in the treatment of carcinoid syndrome, a late stage problem in s-i-NET. Telotristat is a promising addition to our therapeutic arsenal.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Linder Ekberg K,

Keywords: telotristat, carcinoid syndrome, metastasized GI-NET,

#2791 NEN Skeletal Metastasis Performance and the Correlation with Cell Proliferation: 112 Cases of 68Ga-DOTA-TATE Results Analysis

Introduction: 68Ga-DOTA-TATE PET/CT plays an important role in neuroendocrine neoplasm(NEN)diagnosis and biological charecteristcs evaluation.Skeleton is the second common metastatic organ in NEN after liver and it affects the quality of patient’s life.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Yu J

Authors: Xie Q, Lu M, Li J, Li N, Yang Z,

Keywords: Neuroendocrine neoplasm, somatostatin receptor, PET/CT, Skeletal metastasis,

#2022 CXCR4 Expression on Circulating Tumor Cells (CTCs) and Their Association with Bone Metastases in Patients with Neuroendocrine Tumors (NET)

Introduction: Bone metastases have been described in up to 32% of NET patients and are associated with a worse clinical outcome. Overexpression of CXCR4 in primary tumors appears predictive of skeletal involvement.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Rizzo F, Vesely C, Childs A, Mandair D, Khan M,

Keywords: CTC, CXCR4, bone,